Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara
- Lisa Ferrara, Ph.D., brings over 30 years of experience in orthopaedic medical device innovation and regulatory strategy in the USA
- Dr Ferrara will play a pivotal role in advancing Renovos’ lead product RENOVITE® BMP-2 through FDA regulatory approval in the USA
- RENOVITE® is a synthetic, biodegradable nanoclay carrier that is a novel therapeutic delivery platform for precision regenerative medicine
Southampton, UK, 19 September 2024 – Renovos Biologics (Renovos), today announces the appointment of Lisa Ferrara, Ph.D., to its Board as a Non-Executive Director.
The appointment of Dr Ferrara, who has extensive experience developing new orthopaedic devices in the USA and obtaining regulatory approval for them, comes as Renovos presses ahead with development of its lead product RENOVITE® BMP-2, a next-generation precision drugs carrier.
